Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis

Circulation

Volumn 102, Issue 8, 2000, Pages 840-845

  Belton, Orina ^a   Byrne, Dara ^a   Kearney, Dermot ^a   Leahy, Austin ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Atherosclerosis; Cyclooxygenase; Prostaglandins

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; NIMESULIDE; PROSTACYCLIN; THROMBOXANE A2;

AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISCHEMIC HEART DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE;

EID: 0034702914     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.8.840     Document Type: Article

References (49)

1. Atherosclerosis: A defense mechanism gone awry
2. Low density lipoprotein oxidation and its pathophysiological significance
3. Activation of monocytes/macrophage functions related to acute atheroma complication by ligation of CD4: Induction of collagenase, stromelysin and tissue factor
4. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of atherosclerotic plaques
5. Increased prostacyclin in patients with severe atherosclerosis and platelet activation
6. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxidases
7. Arterial walls generate from prostaglandin endoperoxidases, a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation
8. 2 but not of systemic prostacyclin by controlled-release aspirin
9. 2 synthase in human monocytes
10. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease
11. 2 synthase antigen in smooth muscle cells
12. 2 isoprostanes in human atherosclerotic lesions
13. 2(α) is increased in hypercholesterolemia
14. 2(α)
15. 2(α) by human monocytes: Discriminated production by reactive species and prostaglandin endoperoxide synthase-2
16. 2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor is a platelet thromboxane/endoperoxide antagonist
17. 2 receptors
18. Human cyclooxygenase-2 cDNA
19. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
20. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
21. Selective cyclooxygenase-2 inhibition by nimesulidc in man
22. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
23. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids
24. Oxidative damage of cardiomyocytes is limited by ERK1/2-mediated induction of cyclooxygenase-2
25. Molecular cloning of human endoperoxide synthase type II and demonstration of expression in response to cytokines
26. Transcriptional regulation of prostaglandin synthase-2 gene expression by platelet derived growth factor and serum
27. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles
28. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human endothelial cells
29. Pharmacological analysis of cyclooxygenase-1 in inflammation
30. Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
31. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
32. The effects of the novel anti-inflammatory compounds NS-398 and L-745,337, on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthase
33. Reduced fetal exposure to aspirin using a novel controlled release preparation in normotensive and hypertensive pregnancy
34. 2(α) during coronary reperfusion: A potential marker of quantitative oxidative stress in vivo
35. Comparison of anti-desmin and anti-actin staining for the computerized, analysis of cavernous smooth muscle cell density
36. Human atherosclerosis. II: Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions
37. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
38. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina
39. Differential inhibition of prostaglandin endoperoxide synthase isoenzymes by aspirin and other NSAIDs
40. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
41. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity
42. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
43. Low-dose and high-dose acetylsalicylic for patients undergoing carotid endarterectomy: A randomised controlled trial: ASA and Carotid Endarterectomy (ACE) Trial Collaborators
44. Platelet activation in unstable coronary disease
45. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
46. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
47. Cyclooxygenase-2 expression in human and mouse atherosclerotic lesions
48. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apo-E deficient mice
49. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions